Mink Therapeutics Inc (INKT)vsModerna Inc (MRNA)
INKT
Mink Therapeutics Inc
$12.00
-1.07%
HEALTHCARE · Cap: $57.82M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
INKT leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
INKT
Avoid16
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INKT.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INKT
INKT has a balanced fundamental profile.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : INKT
The primary concerns for INKT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
INKT profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MRNA generates stronger free cash flow (-563M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 16/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mink Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?